Company / Net Income
Fulcrum Therapeutics, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$74.9M
FY2025
5-year range
-$109.9M / -$9.7M
FY2021-FY2025
Trend
-670.0%
vs FY2024
Sector context
#94 of 216
Health Care
What the data says
Net Income changed -670% YoY in FY2025, a notable deviation from the 7-year average annual change of -108%.
Based on SEC 10-K filings.
-$75M in FY2025.
Improved from -$97M to -$75M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 216 in Health CareTop 44% of 216This company -$74.9M Sector average $454.3M
▼
-116.5% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 670.0% year-over-year.
- Ranks #94 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$74.9M | -670.0% |
| FY2024 | -$9.7M | +90.0% |
| FY2023 | -$97.3M | +11.4% |
| FY2022 | -$109.9M | -35.9% |
| FY2021 | -$80.8M | -14.2% |
| FY2020 | -$70.8M | +14.3% |
| FY2019 | -$82.7M | -153.7% |
| FY2018 | -$32.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026